Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

Cardinal Health's (CAH) Arm Unveils Supply Automation Solution

Cardinal Health's (CAH) business introduces new offering for clinical labs that can enable them to focus on patient care.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

PacBio's (PACB) New Solution to Boost Public Health Protection

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM

Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.

Baxter's (BAX) $100M Investment to Strengthen Global Presence

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock

McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

McKesson (MCK) Hits 52-Week High, Can the Run Continue?

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

McKesson (MCK) Beats Q2 Earnings and Revenue Estimates

McKesson (MCK) delivered earnings and revenue surprises of 31.69% and 6.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Veeva Systems' (VEEV) eConsent Solution Gets Adopted by Celerion

Veeva Systems' (VEEV) solution gets adopted by Celerion in a bid to boost paperless clinical trials.

Here's Why You Should Add STERIS (STE) to Your Portfolio

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.

Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail

Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Henry Schein (HSIC) Dental Sales Grow Globally Despite Pandemic

Widespread network and channel mix along with favorable long-term trends in the dental business bode well for Henry Schein (HSIC).

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer

Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.